Floatz logo

Tolinapant

Recurrent Ovarian Carcinosarcoma

National Cancer Institute (NCI)Phase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Recurrent Ovarian Carcinosarcoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Carboplatin
University of Oklahoma
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 2B
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2B

View all 35 →

Same molecule, other indications

Tolinapant is also rated in:

ovarian serous adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
fallopian tube carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →